Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor EmpagliflozinLivia Stanger, Michael Holinstat, Bertram Pitt et al.|Blood|2024Cited by 5
Abstract 4134384: Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and ThrombosisLivia Stanger, Michael Holinstat, Adriana Yamaguchi et al.|Circulation|2024Cited by 1
Abstract 4137045: Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic PotentialLivia Stanger, Michael Holinstat, Björn Dahlöf et al.|Circulation|2024Cited by 0
Selectivity and Long Action of <i>In Vivo</i> Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Compared to FDA-Approved Prostacyclin Agonists Iloprost and Selexipag in the Prevention of ThrombosisLivia Stanger, Michael Holinstat, Björn Dahlöf et al.|Blood|2024Cited by 0